lobbying_activities: 2269027

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2269027	905cd0f9-1071-4c8e-85e4-8d88b8a0b7a9	Q1	KOUNTOUPES DENHAM CARR & REID, LLC	320918	ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)	2019	first_quarter	PHA	Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.	HOUSE OF REPRESENTATIVES,SENATE,White House Office	60000		0	0	2019-04-17T12:14:16.117000-04:00